NASDAQ · PRAX
Praxis Precision Medicines, Inc.
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
Loading market information…
NASDAQ · AMLX · USD
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Amylyx Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.29% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Amylyx Pharmaceuticals, Inc.’s forward annual dividend is $1.68 per share, paid quarterly. The forward yield is 5.86% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
BEHIND THE RESULTS
Amylyx Pharmaceuticals, Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.38. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Amylyx Pharmaceuticals, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| $0.00 |
| Q4 2024 | Mar 4, 2025 | -$0.55-12.24% vs estimate | $665.00K |
|---|
| Q3 2024 | Nov 7, 2024 | -$1.07-78.33% vs estimate | $416.00K-98.68% vs estimate |
|---|
THE ANALYST VIEW
11 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 5 contributors · Median target $55.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$288.62+$3.14 (+1.1%)
Praxis Precision Medicines, Inc.’s quoted price sits in the upper half of its reported 52-week range, 26.5% below the high.
$44.39-$0.51 (-1.14%)
Ionis Pharmaceuticals, Inc.’s quoted price sits in the lower half of its reported 52-week range, 48.82% below the high.
$19.32+$0.03 (+0.16%)
Denali Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 29.23% below the high.
$8.88-$0.22 (-2.42%)
Prothena Corporation plc’s quoted price sits in the lower half of its reported 52-week range, 24.75% below the high.
$3.04+$0.28 (+10.14%)
Eledon Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 33.91% below the high.
$2.37$0.00 (0.0%)
AC Immune S.A.’s quoted price sits in the lower half of its reported 52-week range, 39.23% below the high.
$1.30$0.00 (0.0%)
Anavex Life Sciences Corp.’s quoted price sits in the lower half of its reported 52-week range, 84.43% below the high.
$11.08+$0.01 (+0.09%)
ProMIS Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 59.56% below the high.
